0000947871-15-000216.txt : 20150319 0000947871-15-000216.hdr.sgml : 20150319 20150319171035 ACCESSION NUMBER: 0000947871-15-000216 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20150318 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20150319 DATE AS OF CHANGE: 20150319 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QUEST DIAGNOSTICS INC CENTRAL INDEX KEY: 0001022079 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 161387862 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12215 FILM NUMBER: 15713559 BUSINESS ADDRESS: STREET 1: 3 GIRALDA FARMS CITY: MADISON STATE: NJ ZIP: 07940 BUSINESS PHONE: 9735202700 MAIL ADDRESS: STREET 1: 3 GIRALDA FARMS CITY: MADISON STATE: NJ ZIP: 07940 FORMER COMPANY: FORMER CONFORMED NAME: CORNING CLINICAL LABORATORIES INC DATE OF NAME CHANGE: 19960903 8-K 1 ss421592_8k.htm CURRENT REPORT
       
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 

FORM 8-K
 

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of Earliest Event Reported): March 18, 2015

Quest Diagnostics Incorporated
(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or other jurisdiction of Incorporation)
 
001-12215
(Commission File Number)
16-1387862
(I.R.S. Employer Identification No.)
 
 
 
  
Three Giralda Farms
Madison, NJ
(Address of principal executive offices)
 
07940
(Zip Code)
(973) 520-2700
(Registrant’s telephone number, including area code)
 
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation the registrant under any of the following provisions (see General Instruction a.2. below):
     
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 
               
Item 8.01 Other Events
 
On March 18, 2015, the Company issued a press release announcing the pricing for its previously announced cash tender offers to purchase up to $250,000,000 combined aggregate principal amount of its 6.950% Senior Notes due 2037 and 5.750% Senior Notes due 2040 (the “Tender Offers”). A copy of the press release, dated March 18, 2015, announcing the pricing of the Tender Offers is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference into this Current Report on Form 8-K.
 
On March 19, 2015, the Company issued a press release announcing the early tender date results of the Tender Offers. A copy of the press release, dated March 19, 2015, announcing the early tender date results is attached to this Current Report on Form 8-K as Exhibit 99.2 and is incorporated by reference into this Current Report on Form 8-K.
 
Item 9.01 Financial Statements and Exhibits
 
 
Exhibit
Description
     
 
99.1
Press Release Announcing the Pricing of the Tender Offers, dated March 18, 2015
     
 
99.2
Press Release Announcing the Early Tender Date Results of the Tender Offers, dated March 19, 2015
 
 
 
 
 
 
 
 
 
 
2
 
                                 
Signature
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
 
 
March 19, 2015
  
     
 
QUEST DIAGNOSTICS INCORPORATED
  
         
         
  By: /s/ William J. O’Shaughnessy, Jr.  
   
William J. O’Shaughnessy, Jr.
  
    Secretary  
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                               
EXHIBIT INDEX
 
 
Exhibit
Description
     
 
99.1
Press Release Announcing the Pricing of the Tender Offers, dated March 18, 2015
     
 
99.2
Press Release Announcing the Early Tender Date Results of the Tender Offers, dated March 19, 2015
 
 
 
 
 
 
 
 
 
 
EX-99.1 2 ss421592_ex9901.htm PRESS RELEASE ANNOUNCING THE PRICING OF THE TENDER OFFERS
                   
 
Exhibit 99.1

Quest Diagnostics Announces Pricing of Cash Tender Offers for Up to $250 Million Combined Aggregate Principal Amount of Certain of its Outstanding Notes

MADISON, N.J., March 18, 2015 -- Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced today the determination of the pricing for its previously announced cash tender offers (each, an “Offer” and, collectively, the “Offers”) to purchase up to $250 million combined aggregate principal amount (the “Maximum Tender Amount”) of its 6.950% Senior Notes due 2037 (the “2037 Notes”) and 5.750% Senior Notes due 2040 (the “2040 Notes” and, together with the 2037 Notes, the “Notes”). The terms and conditions of the Offers are described in the Offers to Purchase, dated March 5, 2015 (as amended, the “Offers to Purchase”), and the related Letter of Transmittal.

Quest Diagnostics will pay holders who validly tendered and did not validly withdraw their Notes at or prior to 11:59 p.m., New York City time, on March 18, 2015 (such date and time, as they may be extended, the “Early Tender Date”) the “Total Offer Consideration” of $1,348.59 for each $1,000 principal amount of the 2037 Notes accepted for purchase and $1,208.97 for each $1,000 principal amount of the 2040 Notes accepted for purchase, plus, in each case, accrued and unpaid interest up to, but not including, the settlement date.

The Total Offer Consideration, which includes an Early Tender Premium of $50.00 per $1,000 principal amount of the Notes tendered, has been determined for each series of Notes by reference to the applicable fixed spread over the applicable Reference Yield based on the bid-side price of the applicable Reference Treasury Security, as calculated by J.P. Morgan Securities LLC, the dealer manager for the Offers, at 2:00 p.m., New York City time, on March 18, 2015. The formula for determining the Total Offer Consideration is set forth in Appendix I of the Offers to Purchase. The Total Offer Consideration and the applicable Reference Yields are detailed in the table below.
 
Title of Security
  
CUSIP No.
  
Outstanding
Principal
Amount
  
Acceptance Priority Level
  
Reference U.S. Treasury Security
  
Reference U.S. Treasury Security Yield
  
Fixed Spread (basis points)
  
Base Offer
Consideration (1)(2)
  
Early Tender
Premium (3)
  
 Total Offer
Consideration (1)(4)
6.950% Senior Notes due 2037
  
74834L AN0
  
$425,000,000
  
1
  
3% U.S. Treasury Notes due November 15, 2044
  
2.614%
  
185
  
$1,298.59
  
$50.00
  
$1,348.59
5.750% Senior Notes due 2040
  
74834L AQ3
  
$450,000,000
  
2
  
3% U.S. Treasury Notes due November 15, 2044
  
2.614%
  
175
  
$1,158.97
  
$50.00
  
$1,208.97
(1) Excludes accrued interest.
(2) Per $1,000 principal amount of Notes validly tendered after the Early Tender Date and at or prior to the Expiration Date.
(3) Per $1,000 principal amount of Notes.
(4) Per $1,000 principal amount of Notes validly tendered at or prior to the Early Tender Date and accepted for purchase; inclusive of the Early Tender Premium.

Holders who validly tender and do not validly withdraw their Notes after the Early Tender Date but at or prior to 11:59 p.m., New York City time, on April 1, 2015, unless extended or earlier terminated as described in the Offers to Purchase (such date and time, as they may be extended, the “Expiration Date”), will be eligible to receive the Base Offer Consideration, which corresponds to the Total Offer Consideration minus the Early Tender Premium, plus accrued and unpaid interest up to, but not including, the settlement date.

 
 
 
 
 
The amount of each series of Notes to be purchased will be determined based on the Maximum Tender Amount and the order of priority set forth in the table above and in the Offers to Purchase. Early settlement of the Offers will occur promptly following the Early Tender Date (the “Early Payment Date”). Subject to the terms and conditions of the Offers, Quest Diagnostics expects the Early Payment Date to be March 19, 2015.

Either series of the Notes accepted for purchase in accordance with the terms and conditions of the Offers may be subject to proration so that Quest Diagnostics will only accept for purchase Notes with an aggregate principal amount of up to the Maximum Tender Amount. All Notes that are validly tendered for purchase prior to the Early Tender Date will have priority over any Notes that are validly tendered for purchase after the Early Tender Date. Accordingly, if the aggregate purchase price for Notes validly tendered for purchase prior to the Early Tender Date equals or exceeds the Maximum Tender Amount, no Notes tendered for purchase after the Early Tender Date will be accepted for purchase (even if they are Acceptance Priority Level 1).

Quest Diagnostics has retained J.P. Morgan Securities LLC to serve as the dealer manager for the Offers and has retained D.F. King & Co., Inc. to serve as the tender agent and information agent for the Offers. Requests for documents may be directed to D.F. King & Co., Inc. by telephone at 1-800-814-9324 or in writing at D.F. King & Co., Inc., 48 Wall Street, 22nd Floor, New York, New York 10005, Attention: Krystal Scrudato. Questions regarding the Offers may be directed to J.P. Morgan Securities LLC at 1-800-834-4666 (toll-free) or collect (212) 834-4811.

This press release is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell the Notes. The Offers are being made solely by means of the Offers to Purchase and related Letter of Transmittal. In those jurisdictions where the securities, blue sky or other laws require any tender offer to be made by a licensed broker or dealer, the Offers will be deemed to be made on behalf of Quest Diagnostics by the dealer manager or one or more registered brokers or dealers licensed under the laws of such jurisdiction.

About Quest Diagnostics

Quest Diagnostics is the world’s leading provider of diagnostic information services needed to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at QuestDiagnostics.com. Follow us at Facebook.com/QuestDiagnostics and Twitter.com/QuestDX. The information contained on, or that may be accessed through, our website or our social media pages is not incorporated by reference into, and is not a part of, this press release.

The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements,
 
 
 
 
 
 
 
 
which speak only as of the date that they are made and which reflect management’s current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers or strategic partners and other factors discussed in “Business,” “Risk Factors,” “Cautionary Factors that May Affect Future Results,” “Legal Proceedings,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and “Quantitative and Qualitative Disclosures About Market Risk” in the company’s 2014 Annual Report on Form 10-K and the company’s 2015 Current Reports on Form 8-K.

Contacts: Dan Haemmerle (investors) at 973-520-2900 and Dennis Moynihan (media) at 973-520-2800.
 
 
 
 
 
 
 
 
EX-99.2 3 ss421592_ex9902.htm PRESS RELEASE ANNOUNCING THE EARLY TENDER DATE RESULTS OF THE TENDER OFFERS
                       
Exhibit 99.2


Quest Diagnostics Announces Early Tender Date Results of Cash Tender Offers for Up to $250 Million Combined Aggregate Principal Amount of Certain of its Outstanding Notes

MADISON, N.J., March 19, 2015 -- Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced today the early tender results of its previously announced cash tender offers (each, an “Offer” and, collectively, the “Offers”) to purchase up to $250 million combined aggregate principal amount (the “Maximum Tender Amount”) of its 6.950% Senior Notes due 2037 (the “2037 Notes”) and 5.750% Senior Notes due 2040 (the “2040 Notes” and, together with the 2037 Notes, the “Notes”). The terms and conditions of the Offers are described in the Offers to Purchase, dated March 5, 2015 (as amended, the “Offers to Purchase”), and the related Letter of Transmittal.

As of 11:59 p.m., New York City time, on March 18, 2015 (the “Early Tender Date”), the principal amounts of validly tendered Notes that have not been validly withdrawn pursuant to the Offers and that have been accepted for purchase by Quest Diagnostics in accordance with the terms of the Offers are as set forth in the table below:
 
Title of Security
  
CUSIP No.
  
Outstanding
Principal
Amount
Prior to
Early Tender Date
  
Acceptance
Priority
Level
  
Reference U.S. Treasury Security
  
Reference U.S. Treasury
Security Yield
  
Fixed Spread
(basis points)
  
Aggregate Principal Amount to be Accepted for Purchase
  
Base Offer
Consideration (1)(2)
  
Early Tender
Premium (3)
  
 Total Offer Consideration (1)(4)
6.950% Senior Notes due 2037
  
74834L AN0
  
$425,000,000
  
1
  
3% U.S. Treasury Notes due November 15, 2044
  
2.614%
  
185
  
$176,425,000
  
$1,298.59
  
$50.00
  
$1,348.59
5.750% Senior Notes due 2040
  
74834L AQ3
  
$450,000,000
  
2
  
3% U.S. Treasury Notes due November 15, 2044
  
2.614%
  
175
  
$73,575,000
  
$1,158.97
  
$50.00
  
$1,208.97
(1) Excludes accrued interest.
(2) Per $1,000 principal amount of Notes validly tendered after the Early Tender Date and at or prior to the Expiration Date.
(3) Per $1,000 principal amount of Notes.
(4) Per $1,000 principal amount of Notes validly tendered at or prior to the Early Tender Date and accepted for purchase; inclusive of the Early Tender Premium.

Quest Diagnostics will pay the “Total Offer Consideration” to the holders of the Notes that have been accepted for purchase, namely $1,348.59 for each $1,000 principal amount of the 2037 Notes and $1,208.97 for each $1,000 principal amount of the 2040 Notes, which in each case includes an early tender premium of $50.00 per $1,000 principal amount of Notes accepted for purchase (the “Early Tender Premium”). In addition, Quest Diagnostics will pay any accrued and unpaid interest on such accepted Notes up to, but not including, the payment date for the early tendered Notes, which is expected to be March 19, 2015.

Acceptance of Notes for purchase in the Offers is subject to the Maximum Tender Amount and the order of priority set forth in the table above and in the Offers to Purchase. All Notes that were validly tendered for purchase prior to the Early Tender Date will have priority over any Notes that are validly tendered for purchase after the Early Tender Date. Accordingly, as the aggregate purchase price for Notes validly tendered for purchase prior to the Early Tender Date equals or exceeds the Maximum Tender Amount, no Notes tendered for purchase after the Early Tender Date will be accepted for purchase and Notes not accepted, including Notes not accepted because of proration, will be returned promptly. Validly tendered Notes may no longer be validly withdrawn.

 
 
 
 
 
 
Quest Diagnostics has retained J.P. Morgan Securities LLC to serve as the dealer manager for the Offers and has retained D.F. King & Co., Inc. to serve as the tender agent and information agent for the Offers. Requests for documents may be directed to D.F. King & Co., Inc. by telephone at 1-800-814-9324 or in writing at D.F. King & Co., Inc., 48 Wall Street, 22nd Floor, New York, New York 10005, Attention: Krystal Scrudato. Questions regarding the Offers may be directed to J.P. Morgan Securities LLC at 1-800-834-4666 (toll-free) or collect (212) 834-4811.

This press release is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell the Notes. The Offers are being made solely by means of the Offers to Purchase and related Letter of Transmittal. In those jurisdictions where the securities, blue sky or other laws require any tender offer to be made by a licensed broker or dealer, the Offers will be deemed to be made on behalf of Quest Diagnostics by the dealer manager or one or more registered brokers or dealers licensed under the laws of such jurisdiction.

About Quest Diagnostics

Quest Diagnostics is the world’s leading provider of diagnostic information services needed to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at QuestDiagnostics.com. Follow us at Facebook.com/QuestDiagnostics and Twitter.com/QuestDX. The information contained on, or that may be accessed through, our website or our social media pages is not incorporated by reference into, and is not a part of, this press release.
 
The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management’s current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers or strategic partners and other factors discussed in “Business,” “Risk Factors,” “Cautionary Factors that May Affect Future Results,” “Legal Proceedings,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and “Quantitative and Qualitative Disclosures About Market Risk” in the company’s 2014 Annual Report on Form 10-K and the company’s 2015 Current Reports on Form 8-K.
 

Contacts: Dan Haemmerle (investors) at 973-520-2900 and Dennis Moynihan (media) at 973-520-2800.
 
 
 
 
GRAPHIC 4 image01.jpg GRAPHIC begin 644 image01.jpg M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC M+B!6,2XP,0#_VP!#``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(" M`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@+_Q`&B```!!0$!`0$! M`0```````````0(#!`4&!P@)"@L!``,!`0$!`0$!`0$````````!`@,$!08' M"`D*"Q```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$( M(T*QP152T?`D,V)R@@D*%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W M^/GZ$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&A ML<$)(S-2\!5B7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H MJ:JRL[2UMK>XN;K"P\3%QL?(RKR\_3U]O?X M^?K_P``1"`!&`)\#`1$``A$``Q$`_]H`#`,!``(1`Q$`/P#]_*`"@`HV\OP` M*`"@`H#;R_`*`&G`]J-@_#\#)DU[0H+T:=)K.EQ:@SA!9/?VJ71=AD1^091+ MN8'(3;GG@5A]8P\:GLG7HJI=+V?M(*=WJERWYO1;G(\?@85OJ\L7A8UTU'V+ MKTHU5*2T7(Y*]=M5F:;2/"<"ZG);_9T,DWVN]$D=A;B%%+7 M`-P\D"JS21J%-?)9IQID>53E1]M/'8J"ES8;`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`//U:>_DW7K4G*-Y5I56_:.M*;=3VG,Y*>J:T/9PW#&3PR2&3SPE*I0 MGA8TZU2I'GKUJTH>_BJE>=ZLL3*HW659SYU-WBU9'SM\)?C%X@T/P/IEAK]I M<>*1IOQ;NOA&FN7&H>3J!M?MDT&D:A<>9;S?VDUM%'Y%W(9XIGPC$LQ)/R'# M_$.*PV64:6*A/'/#\15N'?K4JJ53V:JSCAZT[Q?M90BE3JZJ3:O=NY^=<(<9 M8_!9'A:.84:F9/#<6U.$8XVI7Y*_L?:2AA:\W*G/ZTX*+C4;E3DURN3OO[ZW MQ,BLO'OBKP;J^G1Z?9^%_!L7C:7Q`M[YL,VE/<36\T"RY9D\6JG-!T.>4)0E3Y5*,XRT^]$0,CQ7D MQLO.A\TON;R^7#<10Q"RZM'"5'A\TK*E1=/FE6HPFI2HU\524%&E2J*.KYY> MSO'FO=V\_`<;0QT&Q6/P_L8PHT*_)[W+ M5FZ//#FYKOEU_!_Q8E\;7NIIH6D6$MIIMUXCTV^C?6DBUG1-1T%C%:0>(=)- MIYMC#KDHD:RN8&N4CA0NPD++6N7YXLRJ5EA:-.4*%7%X>LO;J.(PM;#2Y80Q M5#EYZ<<1JZNF=&3\6?VU6Q*P&#HSIX:IF.&Q$98R-/&8+$8%N-"& M/PCI.=&ECI*3H58.I%1C=J5T6O@EXR\2>/?`]EXG\165A:SZC58>;DN6GB:M)0Y'"/ M(H*"BI<\W4MS-1;L>P#IQ7OGUXM`!0`4`%`!0`4`5;R\M-.M;F^OKB&SL[*W MEN;JZN'6*"VMX4:2:::1B%2.-%9F9B``,U$YTZ,)U:DHTZ=.,ISJ2:C"$(KF ME*3=K)+5OL95JU'#4:N(KU(4*-"G.K5JU)*%.G3@G*#X-0UC3O$.CV$4EEXEUV#3)S#]LL)XY#+-IKQ MYG;2HQ;W=S!(CL)>;>OS;B+%9KQ)DGU[AC$2>7QJ8FCB\/2A*EC<5&A4=/FH M5%*[I-)R]BN2=2$E)-_"?AG'6/XCXUX3_M/@/%U9933Q&,P^98.A%T$88[$Y[G&84']7H8:KDM&%6#3=;&4VL8 MVI*_-2P\O92B_>3K)L^>(O@GXVU#XGZ[\+O#NE37NIZ'J]Q937D@:*PL=)$N M^RU74[LILM[>6RE@F49:6=V,<"2/P?DH\-9C5SO%Y%@\/*I6PN(E3E5:E&A1 MP[E>E5JU-HP=*46H[RE>,4?FRX`SW$\6YCPIEN$G5KX'%U:$Z\N:&'P^#4V^6"E)C_C=\-M/^%'BRQ\%VNHR:M>6WAO3+_7K^55B MAGU749+EI(K*W&3#9PPQ1K$DK-*^XR2'+;5.)LDH9#F%'+8598BI'!4JV*JR MLHSKU)2;C"'_`"[IQ27+%N4FM63Q]PMA>#LYPN24,34Q=>GE>&KX_$32C">+ MQ$JCG&C3_P"75&$(Q4$VYN[2W5H]K/?\`@Z>Y MD+R6;6P,M_HBRR'=]F:'==V<>6$3)+$B@28'W7AQQ#5]K+(,94(M)UK2M!U.0(;5+V32G MLR;+4XHDWK'J>HZ?87UTIGMIC;MLKYN6=ULOPL<+C*D<)#DAAL/GN+HUZ.&K M.W(JLZ7LU[&M'32M5HTZL_>A+E=CX1\58S*L##+,PJ0R^FZ4<#@>+$;KP9X5^'_PN\7:!J_B M#PEXDTCXD.]QJ,=__;]U:ZBT^J7VM7.E"Y^Q/K%Q<2B&<1NL3B...&2.,D1_ M9&`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`KJX?R[&Y3@89?7EAZE/#3K^RK4G-2K1J5IU(.< M'%*E*,96DHN=Y*Z:1Z/!V39GP_EE/)\:\'4H82IBGA\3AIU?:8B%?%5:\)5* M4Z<(T'&G44)QC.KS35XR2T/7AP/3'Z9KW_Z['UPM&WE;Y6N`4;>5OE:X!0`4 M`%`#2/Y?3_/_`->C;;=?+1AMZ_=_6Y\Y?M`^"?''Q8\,/X.^'WB3P[IMO#?! M?&%K>75U'>76R&"ZL=(DDL8K@VD$RS)>7,-PB-<1_9Q_J699Y@7E MV4XW"8:$:J680J3J*I4BHQJ4\,W23]G&?-&&W"F94>+<1@L%AL)CZN*I8F%=5*3I5Z5*+A32C&HYRJ0:IT^ M15)N6D3R?4/VW/"6CWU_:^`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`SI05:%/D=24*,YU5#WE"ZL;WA*U^%/P_M/#,_P`.O"R1 M:9\2;ZWCL]6\*Z3-?6DB2VKW=M>:S?J7DL=,1-R(9W6*"=O*$2/N`WRVGD.4 MTL%+)L#"GA\XJ1]E7R_#RJ4I*5.52%3$55=TJ/+=)S:C&3Y+)NQWY11X5X?I M994X=RM1PW$5:G&ABLKPLZ])PG3=6G5Q>(NY8?"I-I<[4(3;CR1:E;VP8&.@ M/8=#CV'7%?2;>7DO^!T/M=$[;=NGY`"O8@=@.GY#_"A?=VW#[E]P<`\#'TXQ M^5/;I^%@VZ6^7X`"O;'X?EV]^*/30-MO\@!`Z$=<=1C/I]?;K26FWX!^'FM! MK,D:LS,J(@+.S,%50H+,68D!550222`!R:-(W?PI*[>R5N[\O783<8IR;44M MVW9))-MM]$E=N_0Y;7?%^FZ%I.FZRMMJ>L66J:EI>F6C>'K&75I&.K3""WO7 M2VSLTV,D27-Z3Y4,.'.01GBQ..HX2C2K\E:O3K5J%&#PE)UW^_ERPJ-4[VI1 MO>=1^[&/O,\S'9MAL#A<-C%3Q.,HXO$87#47E]%XJ5\5+EIUI*#M'#Q^*I5; MY81U>Z1U8P,#@$G'&!T[=J[?P?\`3T/45EY?AJ&5[<8R?3&/UI[;?Y!IM;^D M*.G'X4;;=-OF&WE;\+D-S/':6\]U*=L=M!+/(<9VQQ(TC'`YZ*>!U^N*FWDF?G1^SRWQRO?BYXC\?KX8 MU.+P-X[U:[N/$$FO,VDVYLC/(-(U#2;>[VW-S=:9;^5!'Y%N8YK4R0F1:8BI/%O$R="#II\N'JX6G/WY5*,5&&D5&=-M#)4<5RQ'$G%F"X8I5)4L)AN2>(Y=4I2I^VK5G'2\Z5!J-)2 MNE.3EUN8>(M3&<<^(N54?AE.CA.6G14](S ME-Z!RG+L-AJ-.*BY>SA*M6:6M2O6E'VE6I)W-N$\'C=*I M\<9*UVF?F'BOX=Y9F>38S/\`*\+2P.=Y51GC/:82FJ/UVA1_>5J5:%-1C*M& M*=2C62552BHN3C*RWO@E\1O&WQ`_9];4]`CLM3^(6C6]]X;MWU6Y-M;W>HV$ M40L=0O)@C_O&LYX)7W@"XN8F,LBB1F'5PUG&8YOPE]8P:I5LWP].K@X.O4Y( M3Q%))4ZM623M>$HS=T^:2=WJV>EP%Q+G7$?AY];P*HU^(L'2Q&60EBI^SIUL M5AXQ6'KUI)/5TJD)2YOXE2+.KXF<;TJSHWJ3FJ\;TY1G)KE@I,KQ4Z6(^K<^)J5(8NE>A4C*:VA+12C&R;2/UG\487PUXB/"@:%J MY/('73[CN>!_G-?O6-TP6,MI_LN(2\OW4^WY(_L#-K+*`_!*_TW3_V6_#%]J-S;6^GVG@367O)IY8U@CA635?,64L0O(.W8>6)"@%B` M?EN&ZM&EP5@*M:<(4:>5UO:SE**C&$?;"*^'PWA9EE;%5*=/# MTLAQKKRJ2C&$8*6+YXR;:2=O=Y7JV^6U]#QKX>6GB3PY\,/V8_M-[K&D2ZA\ M2H(#IR7]Y9177AK69-3O+6PU&P65(KB$QK#/%'9Y9POX7QJ5\9 M@YXGB>$)8=5ZM"-;+<6\55IX;$T8RC&I2<5"I&%1-*ZDE[QU?Q0UV"TT?QCK M?@[6O$&HZOX=^(VB1:AXOO=9EM+71KZXUG3;>X\&Z!:0>7'?V5G:W!M[JU:V M2S/GR>==7,ZX7TL[QE.GA,PQ678K$U,1@LXPT*V.G6<*>&JRQ-&%3`8:"Y8U M*=.$^2=-QY/?;E4G)67K\59A"A@SJT?9QH-SDY5:E1:=)XTEUVZ\5?%RSO'\2WVH0>%M'F^ M%D'A66_>/3+R?3Y9UZ\< MIP<^&*>5SJM8:M/#S7_+B7+A\;+&\M2<\2X*>&UA)TKE3Q)X>UOPS9_`:SN- M=\1Z;K>O^.].M?&*6_B35;F.YN=5T*YGUJR47%W-$+9[N!C$D8V6K/(;,Q#8 M1EC<+;G M/F>!Q^5T>`*%3'9CAL=C\_P]/.8TLQQ4XUJN*P-2>,HOVE6:=%U:;Y8I\E)N M;HN-TUROCO7_`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` MT=6C/;EZ><8WB*.,Q%:D\%F'U##4J-:>'EA,-2I0G#$0Y&OWN("H4<;@Z[]ME>(4:=!X;&X>]IX2O5:E.<4Y)UE)]+<.:XO'Y1Q(L9CHXC'\. MXG,\KPV%S/+,=*.)R/&15#"K+LRP:DH5L%CL3/VM:7+=RK\TG*3II?7(X'IC M],U]UM\OU/ULYOQC)>6_A3Q//ILCP:A#X?UB2QEBXEBNX["X>WDC/.'24*R\ M?>QUKDQ[G#`XR5)N-6.%KNG*.CC-4IN+3Z-2LUYGFYQ*M3RG,YX63AB(9?C) MT)QTE"K'#U'3E'3=3LUYH_$Z+X[?&?RT_P"+E^+1\N.-28`8ZX&WC!_R:_FJ M'%'$G+'_`(6\#GG7XX^'+^]&N^+;%F/BW5+>RN1)>6\MPNZ60W/AV: M&&)!'^^2T$2`L#7W>!I5)\'4J1Q684K?7Z\:-1.K"4[7?M<(X M+E2L^2RU1^PY12Q6>>&N+XIR1N/'>7U\1]?S>A=YKB50JWMY!!!<2O M]KU$B".-4N(PD44%Q,Y5RWE@?-APW+,\VP=3-,TXQQ>6X.G7EAH05>E1J3J4 MU%S_`'E9)/$C,-HX>M4K M4Z<*LY.KB7[.-E4C:,:=24K2ORJS?8>-?AA\;=8TN6_^$7QTU'XG>'+R*6TO MM-G\0:?%>B*9&62$7D#G3;M)(F*212M93#<0$?)(]+,LCXDQ%&5;A_BFMG&# MJ1E3J4*F*H*HH25G"-6E:C.+3:DIJ$]>I[6>\*\=8W!RQ'!G'V(XFRVM3E1J MX6IF&']KRS34XJO";PU:,X.SC)T9J^D9)Z>"7O@3X_?`?P!-XAG\377@/2KK M6[.TC\.:7K$,ISG53BZL^2]."BE_,Y.VJ1^]^\E)Z>[%*Y]C?LCQ_$G7/#FH^//'_BC M7]9M=<867A?3]7N6EB33[60FYU>.-U7!O+@>1;N#S##*>CK7Z'P`LZQ."K9I MFV.Q6(ABVJ>`HUYWC&A3^*NHV3O5G=1?\D>SN?MG@Y'B?'Y5B,_XBS3'XRGC MVJ654,94TDSZPU;2-/UO3KG2M4M_M.GW:& M*ZMC))$MQ$?O12-"\;F-N0Z;MKJ2K@@D5]Y6H4:]*=&K!2I5%RSA=Q3CUB^5 MJZ:T:O9GZ_BL)A\;AZN%Q-/VF'KQ=.K3YI04X-:QDXN+Y6FTU=)IVU.*L/A' M\.=+MH;"R\)Z;!IEO,+B'23Y\ND).&WK*-*EE>P+JX#@FW)#@-][FO/HY'E. M'IPHTL#1IT*;O'#I2>'BT[IJ@VZ6^OPZ/7<\7#\)\.X2E'#T,JP]/"PG[2.# M_>2PGM-^9X6WU-[7O!?ACQ/-I4^NZ1!J$FA7"WFCM(TT?\` M9MVF-EU:+#)&L-Q&`%291YB+E%(4D'IQ.78/%SH3Q.'A4EA:D:F'D^9>QJ1^ M&I346E&:V4MU>UTM#OQV399F4L'/&X.G7E@*JKX)R$'V\VWG>1!J!\M" M;^VCBNRRAO.W.ESXN-FHUJBM^]<5+DC6T3]K%1J72]X\ M^KPEPY6EF$JF58::S67/CX-3]G7JI+]][/G5.%?W4_;THPJMJ_/?4\3U?X5: M!?\`BSQ7<^+?#WBJRAAM]*L/!=[X!O-?M%N]!T[3EA@COY](O/WVN6]UYL>_ M6$C18_*\N22+>]?/8G(L+6QV-GF&$QE)1A1H9?5RRMC*4IX6E22@JLL-47^T M0JH6D9PZ"4J6SZF6Y0Y9=EU/.8O%XO`MSH MU:\^:O3:G+V$I3@TI8B%+EC.:N[WU>I]%D7#*>VB"@P0NA2!OFA"-S7I?V5E[KXC$O"4I5\725#$ MU)7;KT5\-.IS74H1^RFK1>UF>]+A_)I8K&XV67T*F)S&@L-CJE12J?6L.DHQ MHUXSXD@T>!Y;C2WT1Y[V6YOYUT:12LFE0 M37LUQ);:?*K$/:P/%"_&Y&VKBZ>6X*G*4HT(\\J+PW/-RJ26'>]!.HY.%)[. M$;1:Z;6JED654)3G#!TY3GA7@93K2J5YK!M-2PD)5I5)4\,TVI4J;C"75:)B MZ=X%\*:4MPEGHMLL=SIAT65+AIKQ1HS"0-I$*W5Z$+0=]8]L;_A4GP\_L:+P\WAJUET6WN+>Y@TZ> MXO9K>&:S`%CY0EN7*16(Q]A@4B&S8!K=(VYKG>1Y5]5C@W@J4L-"=.I&A)SE M",J3O2LG)^[2>M..D86T2./_`%3X>6!CEO\`9E)X&G5IU:>&E.M*G"=%6HXT.`ZC)9V^GW5U%/=V\FI65H`+:UU M86\\2:M#`HV1+J(N<)E`=I(K:KE>`J5G7EAH^VE"%*I5BYTY5:=/^'"LX2C[ M:,+M*-7FLKI:'16X>R>MBGC)X&FL3.C3P]:M"52E/$T:/\.EB_93@L5"&T57 M53E5TM'8YS6K;X7>'_$FFP:M:6MIK.N:A;ZC;VZI>O8W&I6:K!8ZC>VL1.G" MYMA"D=I-D$(9.2O'*,+BJ4:T(4Z^(JQK0@E-4YU::2IU:D8_NN> M*BN24E=)7Z77GXVEPQ@LQH0Q=*C0QF/Q-/$PI\M7V-;%8>,84<16I0_V?VM. M,(JE4J1O'D4DUR)KUL=!_P#JZU[?IIV\CZK\/T_K\1DL<WWPQ^(GB'PQ=0R1V:7DVH:!<%"L=[H5],\]E+"WW6,"LUIIBM_!? MQ%-J%I;G5?#VK+%!XBT%I1$+J.(GR;RR=@4AU*T#R")G7RYHG>"7`8.O7PSQ M)B.&L9.K"FZ^#KJ,,7A5+E;4+\M2E?W8UH7:5_=E%N+W37?P!QWCN!LSG6IT MWB\LQO)#,7F:3;ZGZ%Q=+PEXB MR7,\\R?%2RW/50J8JAEBE4P<:V-DX\T:F"E">&=2J]:CPLXJ;BFW>[/DWPKX MS\6>!;UM0\'^(-4\.7)]I.1BO@G)V_FB[(_%\ES_.N'JTL1DF98K+*LTHU'AZG M+2J13YHQJ4;2IU+-MKFC+Y7/J#X3_#KXF_M,:]9^(OB3X@UZ]\`:/SIXEIW]AA*<8PA9O2K74=%[J;;L?KO!_#7%?BCC\/FG%68X^MP[@JO- MSUVZ5/&2BUS8;`T(*%.//M7Q$8)0A>*&T ML[6!!'#;VUN@BAAB1>%2-%"KZXR>37[E2ITZ%.G2I0C3ITHQITH17+&$(I1C M&*TLDDK(_K>A0HX2C2PV'IPH4,/3A1HTJ:Y84J5.*A"$(KX8QBE%+LBYT]L? MAC-:+[OZ_4U"@`H`*`$Z4;>7X```'08Y^GO2T6JT#;RM^%Q?I3_#R[`%`!0` M4`'2C;^K!^'X'+:QX-\/Z[J5CJNIV(GOM-*?9I!++&N(Y/.C2:.-U29$ERP5 MP>&9&S&S*>.O@<+B*M*M5HIU*33C*\H[-M7M9=]'T;6S:/,Q>48#&XBABL10 M4Z^'M[*7-**T?,E.,6E)1DVTI7W:=XR:.H'05V;:=CT]OE^HO3V_2C_ANP;> M5OE:YY%\7O@SX1^,.B)INOQ/::E8^9)HGB"R5%U'29I!\ZJ6&VXLYB%^T64O M[J7:&4QRA)%\#/\`AW`<0X98?%1=.K2N\-BJ22KX>< M89-^SJ4<1#"UW!-V52CBI4U"7>-.I.-WNS`TO]DOXZ:G,J2>$[31TW8:ZU;6 MM,BBC&<%BEI/=W&.^$A;CH":Y*'`'$U67*\!2P^J3J5\31BDNZ5-SF[=E$\W M!^#7B!BJBC/*@:-/;ZM\2=8 M'B>ZA9)%T#3$ELM"5T8,%O+ARM[J,8(YB"V<+=)$D4E3]SDOAG@\+*%?.:_U M^I"TEA:2=/"IK5*HW:I65_L^Y!]5(_7N%?`?*\OJ4L7Q-BUFM:FU*.7X>,J& M`C*-I*-6;M7Q,4_LM4HM.TE)7O\`